Solid Lipid Nanoparticles (SLNs): A Promising Approach for Enhanced Drug Delivery

Drug delivery systems play a crucial role in modern pharmaceutical sciences by ensuring that therapeutic agents are delivered to the desired site of action at an appropriate rate and concentration. The primary objective of any drug delivery system is to achieve maximum therapeutic efficacy while minimizing adverse effects and improving patient compliance. Conventional dosage forms such as tablets, capsules, injections, and topical preparations are widely used; however, many drugs suffer from poor aqueous solubility, low bioavailability, rapid metabolism, instability in biological environments, and the need for frequent dosing. These limitations often lead to inconsistent therapeutic outcomes and reduced patient adherence to treatment.

To overcome these challenges, Novel Drug Delivery Systems (NDDS) have been developed to improve the pharmacokinetic and pharmacodynamic performance of drugs. NDDS are designed to enhance solubility, protect drugs from degradation, provide controlled and sustained release, and enable site-specific or targeted delivery. Such systems help reduce dosing frequency, minimize side effects, and improve overall therapeutic effectiveness. Examples of NDDS include liposomes, niosomes, polymeric nanoparticles, nanoemulsions, dendrimers, and lipid-based nanoparticles.

Nanotechnology has revolutionized pharmaceutical formulation by enabling the design of carrier systems in the nanometer size range. Nanoparticles possess a large surface area, improved dissolution characteristics, and the ability to cross biological barriers more effectively than conventional systems. These properties make them highly suitable for delivering poorly soluble and unstable drugs. Nanotechnology-based formulations have been extensively investigated for oral, topical, transdermal, ocular, pulmonary, and targeted drug delivery applications.

Among various nanocarrier systems, lipid-based carriers have gained particular attention because of their excellent biocompatibility, biodegradability, and low toxicity. Lipids are physiologically accepted materials capable of incorporating lipophilic as well as certain hydrophilic drugs. Lipid-based carriers also protect drugs from chemical degradation and can provide controlled release. Major lipid-based delivery systems include liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and self-emulsifying systems.

Solid lipid nanoparticles represent one of the most promising lipid-based nanocarriers for enhanced drug delivery. They combine the advantages of polymeric nanoparticles, emulsions, and liposomes while overcoming many of their limitations. SLNs consist of a solid lipid core stabilized by surfactants and are capable of improving drug solubility, bioavailability, stability, and controlled release. Owing to these unique properties, SLNs have emerged as a versatile and effective platform for the delivery of a wide range of therapeutic agents.

Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles (SLNs) are submicron-sized colloidal carriers composed of physiologically acceptable solid lipids stabilized by one or more surfactants. The particle size of SLNs generally ranges from 50 to 1000 nm. In these systems, the drug is incorporated within a solid lipid matrix that remains solid at both room and body temperatures. SLNs were developed to combine the advantages of polymeric nanoparticles, liposomes, and emulsions while minimizing their limitations, such as toxicity, instability, and the use of organic solvents. Because of their lipidic composition and nanoscale size, SLNs offer improved solubility, enhanced bioavailability, protection of drugs from degradation, and controlled or sustained drug release.

The concept of SLNs was first introduced in the early 1990s by Müller and co-workers as an alternative to polymeric nanoparticles. Since then, SLNs have attracted considerable attention in pharmaceutical research because they are prepared using biocompatible and biodegradable lipids that are generally recognized as safe. Over the past three decades, significant advancements have been made in formulation strategies, manufacturing methods, surface modification, and targeted delivery applications, making SLNs one of the most extensively studied lipid-based nanocarrier systems.

The basic structure of SLNs consists of a solid lipid core surrounded by a stabilizing surfactant layer. The solid lipid core may be composed of triglycerides, fatty acids, waxes, or glyceride mixtures such as stearic acid, glyceryl monostearate, tristearin, and cetyl palmitate. This core acts as a reservoir for the incorporated drug and controls its release. The outer surfactant layer, formed by agents such as Tween 80, Span 60, and Poloxamer 188, reduces interfacial tension and prevents aggregation of nanoparticles, thereby enhancing physical stability and uniform dispersion.

Drug incorporation into SLNs can occur through three principal models. In the homogeneous matrix model, the drug is uniformly distributed throughout the lipid matrix, resulting in sustained and controlled release. In the drug-enriched shell model, the drug is concentrated near the outer shell of the nanoparticle, often leading to an initial burst release followed by slower diffusion. In the drug-enriched core model, the drug is concentrated in the central core and surrounded by a lipid shell, providing prolonged release and better protection from external conditions. The mechanism of incorporation depends on factors such as drug solubility in the lipid, preparation method, cooling rate, and lipid crystallization behavior.

Due to their unique structural characteristics and versatile drug incorporation patterns, SLNs have emerged as a highly effective and adaptable platform for improving the delivery of a wide variety of therapeutic agents through oral, topical, transdermal, ocular, pulmonary, and targeted drug delivery routes.

Materials Used in SLN Formulation

Materials Used

Drug Profile of Ibuprofen

Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivative class. It is chemically known as (RS)-2-(4-(2-methylpropyl)phenyl) propanoic acid and has the molecular formula C₁₃H₁₈O₂ with a molecular weight of 206.28 g/mol. Ibuprofen is a white to off-white crystalline powder that is practically odorless and exhibits a melting point of 75–78°C. It is practically insoluble in water but readily soluble in organic solvents such as ethanol, methanol, acetone, and chloroform. The drug has a pKa of approximately 4.9 and a log P value of about 3.5, indicating its lipophilic nature. According to the Biopharmaceutics Classification System (BCS), ibuprofen is classified as a Class II drug, characterized by low aqueous solubility and high intestinal permeability.

Ibuprofen exerts its therapeutic action by reversibly inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby suppressing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Owing to this mechanism, it possesses potent analgesic, anti-inflammatory, and antipyretic properties and is extensively used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, musculoskeletal disorders, dental pain, postoperative pain, migraine, and mild to moderate fever. Following oral administration, ibuprofen is rapidly absorbed from the gastrointestinal tract, with an oral bioavailability of approximately 80–100%. It is highly bound to plasma proteins (about 99%) and undergoes extensive hepatic metabolism, primarily through the CYP2C9 enzyme, producing inactive metabolites that are mainly eliminated via the kidneys. The elimination half-life of ibuprofen is approximately 2 hours, necessitating multiple daily doses for sustained therapeutic effects.

Despite its excellent pharmacological efficacy, the poor aqueous solubility of ibuprofen limits its dissolution rate, which can affect the onset and consistency of drug absorption. Furthermore, conventional oral formulations may cause gastrointestinal irritation, ulceration, and bleeding, particularly during long-term therapy. To overcome these limitations, advanced drug delivery systems such as solid lipid nanoparticles (SLNs) have gained considerable attention. SLNs can enhance the solubility, dissolution rate, stability, and bioavailability of ibuprofen while providing controlled drug release and reducing gastrointestinal adverse effects. These advantages make ibuprofen an ideal candidate for lipid-based nanoparticulate drug delivery systems aimed at improving therapeutic efficacy and patient compliance.

METHODOLOGY

1. Procurement of Materials

All required materials, including ibuprofen, solid lipids, surfactants, solvents, and other excipients, were procured from authenticated pharmaceutical suppliers. The materials were verified using their Certificates of Analysis (CoA) and stored under recommended conditions to maintain quality and stability.

2. Preformulation Studies

Preformulation studies were performed to determine the physicochemical properties of ibuprofen and its compatibility with selected excipients. The studies included:

• Organoleptic evaluation (color, odor, appearance, and powder characteristics)
• Solubility studies in water, organic solvents, buffer media, and lipids
• Melting point determination
• Drug–excipient compatibility studies using FTIR and DSC

3. Preparation of Solid Lipid Nanoparticles (SLNs)

Ibuprofen-loaded SLNs were prepared using the optimized hot homogenization followed by ultrasonication technique. Suitable lipids and surfactants were selected based on drug solubility and compatibility studies. The molten lipid phase containing the drug was emulsified with the aqueous surfactant phase and subsequently homogenized and sonicated to obtain nanosized particles.

4. Formulation Development and Optimization

Different formulation batches were prepared by varying lipid concentration, surfactant concentration, and processing parameters. The formulations were optimized based on particle size, polydispersity index, zeta potential, entrapment efficiency, and drug release characteristics.

5. Characterization of Solid Lipid Nanoparticles

The optimized SLN formulation was characterized for its physicochemical properties using standard analytical techniques, including:

• Particle size and polydispersity index by Dynamic Light Scattering (DLS)
• Zeta potential measurement
• Surface morphology using Scanning Electron Microscopy (SEM)
• Drug content determination
• Entrapment efficiency
• In vitro drug release study
• Drug release kinetic modeling

6. Incorporation into Final Dosage Form

The optimized SLN dispersion was incorporated into a suitable pharmaceutical dosage form to improve patient acceptability and therapeutic performance. Uniform mixing was carried out to ensure homogeneous distribution of nanoparticles throughout the formulation.

7. Evaluation of SLN-Loaded Formulation

The final formulation was evaluated for its pharmaceutical quality by determining:

• Physical appearance
• pH
• Viscosity
• Spreadability (for gel formulations)
• Drug content
• In vitro drug release/diffusion behavior

8. Stability Study

The optimized formulation was subjected to stability studies under recommended storage conditions. Samples were periodically evaluated for changes in physical appearance, particle size, drug content, entrapment efficiency, pH, and drug release profile to assess formulation stability over time.

RESULTS AND DISCUSSION

Preformulation Study

Organoleptic Properties

Table 1: Organoleptic Properties of Drug (Ibuprofen)

Parameter	Observation
Color	White to off-white
Odor	Odorless or faint characteristic odor
Appearance	Crystalline powder
Nature of Drug	Fine, free-flowing powder

Solubility Studies

Table 2 : Solubility of Drug (Ibuprofen) in Different Solvents and Lipids

Solvent / Lipid	Solubility
Distilled Water	Practically insoluble
Methanol	Freely soluble
Ethanol	Freely soluble
Phosphate Buffer (pH 6.8)	Slightly soluble
0.1N HCl	Very slightly soluble
Stearic Acid	Soluble
Glyceryl Monostearate	Moderately soluble

Melting Point

Table 3: Observed and Reported Melting Point of Ibuprofen

Parameter	Value (°C)
Observed Melting Point	74 – 76°C
Reported Melting Point	75 – 77°C

Drug–Excipient Compatibility Studies

Figure 1: FTIR Spectra of Ibuprofen

Figure  2: FTIR Spectra of drug Excipient

Figure 6.3: DSC thermogram of pure drug and physical mixture

Figure 4: particle size comparison

Figure 5 : Morphological Analysis

Figure 5: In Vitro drug release profile

Among all formulations, F1 and F2 showed comparatively larger particle size and higher PDI values, indicating less uniformity and lower physical stability. F3 showed improvement in particle size and PDI, but its zeta potential was slightly below the desired stability range.

Formulations F4 and F5 showed better results with smaller particle size, lower PDI, and good negative zeta potential. F5 showed the smallest particle size and highest drug content; however, its drug release was comparatively slower. F4 showed an optimum balance between particle size, stability, drug content, and controlled release.

Therefore, formulation F4 was selected as the optimized formulation because it showed desirable particle size, narrow size distribution, adequate zeta potential, good drug content, and sustained drug release up to 12 hours.

REFERENCES

1. Maksimenko A., Dosio F., Mougin J., Ferrero A., Wack S., Reddy L.H., Weyn A.-A., Lepeltier E., Bourgaux C., Stella B., et al. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic longcirculating properties and anticancer activity. Proc. Natl. Acad. Sci. USA. 2014;111:E217–E226. doi:10.1073/pnas.1313459110.
2. Sobot D., Mura S., Yesylevskyy S.O., Dalbin L., Cayre F., Bort G., Mougin J., Desmaële D., Lepetre-Mouelhi S., Pieters G., et al. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nat. Commun. 2017;8:15678. doi:10.1038/ncomms15678.
3. Sobot D., Mura S., Rouquette M., Vukosavljevic B., Cayre F., Buchy E., Pieters G., Garcia-Argote S., Windbergs M., Desmaële D., et al. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Mol. Ther. 2017;25:1596–1605. doi: 10.1016/j.ymthe.2017.05.016.
4. Hussein AA. Ex-vivo Ex-Vivo Absorption Study of a Novel Dabigatran Etexilate Loaded Nanostructured Lipid Carrier Using Non-Everted Intestinal Sac Model. Iraqi Journal of Pharmaceutical Sciences (IJPS). 2019 Dec 22;28(2):37-45.
5. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids and surfaces b: biointerfaces. 2011 Nov 1;88(1):483-9.
6. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH.Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. Journal of colloid and interface science. 2014 Aug 15;428:286-94.
7. Mandal S, Vishvakarma P, Verma M, Alam MS, Agrawal A, Mishra A. Solanum Nigrum Linn: an analysis of the Medicinal properties of the plant. Journal of Pharmaceutical Negative Results. 2023 Feb 1;14.
8. Sohail MF, Akhtar Shah P, Tariq I, Saeedul-Hassan A, Amin U, Raza S, et al. Development and in vitro evaluation of flurbiprofen microcapsules prepared by a modified solvent evaporation technique. Trop J Pharm Res 2014;13:1031-8.
9. Vishvakarma P. Design and development of montelukast sodium fast dissolving films for better therapeutic efficacy. Journal of the Chilean Chemical Society. 2018 Jun;63(2):3988-93
10. Patro N.M., Devi K., Pai R.S., Suresh S. Evaluation of bioavailability, efficacy, and safety profile of doxorubicin-loaded solid lipid nanoparticles. J. Nanopart. Res. 2013;15:2124. doi: 10.1007/s11051 013-2124-1.
11. Ma P., Mumper R.J. Anthracycline nano-delivery systems to overcome multiple drug resistance: A comprehensive review. Nano Today. 2013;8:313–331. doi: 10.1016/j.nantod.2013.04.006.
12. Kang K.W., Chun M.-K., Kim O., Subedi R.K., Ahn S.-G., Yoon J.-H., Choi H.-K. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed. Nanotechnol. Biol. Med. 2010;6:210–213. doi: 10.1016/j.nano.2009.12.006.
13. Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 2009;6:1017–1032. doi: 10.1517/17425240903167942.
14. Battaglia L., Muntoni E., Chirio D., Peira E., Annovazzi L., Schiffer D., Mellai M., Riganti C., Salaroglio I.C., Lanotte M., et al. Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: Preliminary study for glioma treatment. Nanomedicine. 2017;12:639–656. doi: 10.2217/nnm-2016-0380.
15. Stevens P.J., Sekido M., Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004;21:2153–2157. doi: 10.1007/s11095-004-7667-5.
16. Neves A.R., Queiroz J.F., Lima S.A.C., Reis S. Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. Bioconj. Chem. 2017;28:995–1004. doi:10.1021/acs.bioconjchem.6b00705.
17. Chirio D., Gallarate M., Peira E., Battaglia L., Serpe L., Trotta M. Formulation of curcumin-loaded solid lipid nanoparticles produced by fatty acids coacervation technique. J. Microencapsul. 2011;28:537–548. doi: 10.3109/02652048.2011.590615.
18. Irby D., Du C., Li F. Lipid-Drug Conjugate for Enhancing Drug Delivery. Mol. Pharm. 2017;14:1325–1338. doi: 10.1021/acs.molpharmaceut.6b01027.
19. Scholes P.D., Coombes A.G.A., Illum L., Davis S.S., Watts J.F., Ustariz C., Vert M., Davies M.C. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J. Control. Release. 1999;59:261–278. doi: 10.1016/S0168-3659(98)00138-2.